Table 1.
Immunotherapies for treatment of neonatal sepsis.
| Author | Year | Study design | N | Population | Outcome | Effect/comnents | |
|---|---|---|---|---|---|---|---|
| IVIG | |||||||
| DeJonge et al.[3] | 2007 | RCT | 1,983 | Infants <1,250 g | Prevention of Staphylococcal late-onset sepsis | NS | |
| Benjamin et al.[4] | 2006 | RCT | 206 | Infants <1,500 g | Prevention of Staphylococcal late-onset sepsis | NS | |
| Trackray et al.[5] | 2006 | RCT | 88 | Infants <1,300 g | Prevention of Staphylococcal late-onset sepsis | NS | |
| Ohlsson et al.[6] | 2004 | Systematic review | 262 | Premature and term infants | All-cause mortality | P<0.05 | |
| CSF | |||||||
| Carr et al.[7] | 2003 | Systematic review | 451 | Premature and term infants | All-cause mortality | P<0.05 (28-day mortality) | |
| Probiotics | |||||||
| Lin et al.[8] | 2005 | RCT | 367 | Infants <1,500 g | Incidence of culture proven sepsis | P=0.03 | |
| Lin et al.[9] | 2008 | RCT | 434 | Infants <1,500 g | Incidence of culture proven sepsis | NS | |
| Honeycutt et al.[10] | 2007 | RCT | 12 | Infants in the Pediatric Intensive Care Unit | Incidence of nosocomial infections | NS | |
| Kukkonen et al.[11] | 2008 | RCT | 939 | Full term infants | Post-natal infections | NS | |
| Manzoni et al.[12] | 2006 | RCT | 80 | Infants <1,500 g | Incidence of bacterial sepsis or invasive fungal infections | NS | |
| Alfaleh et al.[13] | 2008 | Systematic review | 1,284 | Premature infants (<37 weeks) | Incidence of sepsis | NS | |
| Glutamine supplementation | |||||||
| Poindexter et al.[14] | 2004 | RCT | 1,433 | Infants <1,000 g | Incidence of late-onset sepsis and overall mortality | NS | |
| Thompson et al.[15] | 2003 | RCT | 85 | Infants <1,500 g | Incidence of culture proven sepsis | NS | |
| van den Berg et al.[16] | 2005 | RCT | 102 | Infants <1,500 g | Incidence of nosocomial infections | P=0.023 | |
| Tubman et al.[17] | 2008 | Systematic review | 2,240 | Premature infants (<37 weeks) | Incidence of culture proven sepsis | NS | |
| Lactoferrin | |||||||
| Manzoni et al.[18] | 2008 | RCT | 302 | Infants <1,500 g | Incidence of culture proven late-onset sepsis | Incidence reduction, preliminary data | |
| Recombinant human protein C | |||||||
| Nadel et al.[19] | 2007 | RCT | 477 | Pediatric patients, 6% neonates | Time to organ failure resolution and 28-day mortality | NS |
IVIG: Intravenous Immunoglobulin; CSF: Colony Stimulating Factors; RCT: Randomized Controlled Trial; GA: Gestational Age; NS: not significant.